Compare INFQ & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFQ | TWST |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | 205 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2026 | 2018 |
| Metric | INFQ | TWST |
|---|---|---|
| Price | $13.09 | $60.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $20.00 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 8.1M | 1.2M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $8.52 | $23.30 |
| 52 Week High | $21.28 | $66.06 |
| Indicator | INFQ | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 63.34 |
| Support Level | $8.54 | $41.85 |
| Resistance Level | $21.28 | N/A |
| Average True Range (ATR) | 1.77 | 3.52 |
| MACD | 0.08 | 0.76 |
| Stochastic Oscillator | 28.85 | 72.08 |
Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.